UBS research indicates that, owing to capacity limitations, the profitability of generic DRAM is likely to outstrip that of HBM. By 2027, the gross margin for generic DRAM is projected to reach 95%, in contrast to the 75% to 78% range for HBM. This could potentially lead to an even greater disparity between the two.